Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CETP | P11597 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | NQO1 | P15559 | 1/20 | 0.46 |
| ▸ | CTRC | Q99895 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8963436 | 0.86 | HSPA5 (0.67) | CYP2C19CYP1A2CYP3A4CYP2C9CETP | |
| SCHEMBL31145030 | 0.86 | HSPA5 (0.67) | CYP2C19CYP1A2CYP3A4CYP2C9CETP | |
| SCHEMBL2512174 | 0.85 | CETP (0.49) | CYP2C19CYP1A2CYP3A4CYP2C9CETP | |
| SCHEMBL599659 | 0.85 | CYP2C19 (0.62) | CYP2C19CYP1A2CYP3A4CYP2C9TDP1 | |
| SCHEMBL29490353 | 0.85 | CYP2C19 (0.62) | CYP2C19CYP1A2CYP3A4CYP2C9TDP1 | |
| SCHEMBL31145042 | 0.83 | CYP2C19 (0.53) | CYP2C19CYP1A2CYP3A4CYP2C9CETP | |
| SCHEMBL659516 | 0.83 | CYP2C19 (0.60) | CYP2C19CYP1A2CYP3A4CYP2C9TDP1 | |
| Hydrogen Sulfide SCHEMBL11348128 | 0.83 | CYP2C19 (0.60) | CYP2C19CYP1A2CYP3A4CYP2C9TDP1 | |
| SCHEMBL659517 | 0.83 | CYP2C19 (0.60) | CYP2C19CYP1A2CYP3A4CYP2C9TDP1 | |
| SCHEMBL11339937 | 0.83 | CYP2C19 (0.60) | CYP2C19CYP1A2CYP3A4CYP2C9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4590301-A | USING PHENOL OR DIKETONE CYCLOHEXYL COMPOUNDS | BARNES-HIND, INC. (US) | 1986-05-20 | — | — | US | claimed |
| EP-0179476-A1 | Polymerization inhibitors and polymerization-inhibited solutions of monomers | Barnes-Hind, Inc. (US) | 1986-04-30 | — | — | EP | claimed |
| US-8470932-B2 | Scalable process for synthesis of a curable wax | XEROX CORPORATION (US) | 2013-06-25 | — | — | US | disclosed |
| US-8207274-B2 | Solvent-free process for synthesis of a curable wax | XEROX CORPORATION (US) | 2012-06-26 | — | — | US | disclosed |
| US-20110251334-A1 | SOLVENT-FREE PROCESS FOR SYNTHESIS OF A CURABLE WAX | XEROX CORPORATION (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110247521-A1 | SCALEABLE PROCESS FOR SYNTHESIS OF A CURABLE WAX | XEROX CORPORATION (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110247521-A1 | SCALEABLE PROCESS FOR SYNTHESIS OF A CURABLE WAX | HACL2, USP14, USP16 | CYP2C19 1835/4885CYP1A2 892/4885CYP3A4 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.